Danielle Antalffy
Stock Analyst at UBS
(3.47)
# 840
Out of 5,182 analysts
206
Total ratings
48.31%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $120 → $105 | $57.48 | +82.67% | 16 | Mar 17, 2026 | |
| SYK Stryker | Maintains: Neutral | $400 → $380 | $296.00 | +28.38% | 8 | Mar 17, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $12 → $11 | $4.90 | +124.49% | 4 | Mar 6, 2026 | |
| RXST RxSight | Maintains: Neutral | $8 → $9 | $5.98 | +50.50% | 5 | Feb 26, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $17.94 | +22.63% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $28.85 | +90.64% | 14 | Feb 18, 2026 | |
| MDT Medtronic | Maintains: Neutral | $103 → $104 | $78.59 | +32.33% | 13 | Feb 4, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $83.66 | +2.80% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $84.22 | +12.80% | 14 | Jan 12, 2026 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $46.69 | +94.90% | 8 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $145 | $136.19 | +6.47% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $25.35 | +144.58% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $159.19 | +151.27% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.97 | +196.95% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $13.94 | +14.78% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $60.60 | +56.77% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $17.34 | +21.14% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $458.76 | +30.79% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $221.21 | -3.26% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $26.96 | +111.42% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $87.23 | +69.68% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $4.36 | -48.34% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $4.56 | +17,992.11% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $43.84 | -68.07% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $88.87 | +12.52% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $18.68 | -35.76% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $37.23 | +20.87% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $149.64 | +83.77% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.66 | +653.30% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $7.28 | +476.92% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $5.27 | +1,038.52% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.59 | +2,442.80% | 1 | Sep 1, 2020 |
Boston Scientific
Mar 17, 2026
Maintains: Buy
Price Target: $120 → $105
Current: $57.48
Upside: +82.67%
Stryker
Mar 17, 2026
Maintains: Neutral
Price Target: $400 → $380
Current: $296.00
Upside: +28.38%
Sight Sciences
Mar 6, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $4.90
Upside: +124.49%
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $5.98
Upside: +50.50%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $17.94
Upside: +22.63%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $28.85
Upside: +90.64%
Medtronic
Feb 4, 2026
Maintains: Neutral
Price Target: $103 → $104
Current: $78.59
Upside: +32.33%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $83.66
Upside: +2.80%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $84.22
Upside: +12.80%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $46.69
Upside: +94.90%
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $136.19
Upside: +6.47%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $25.35
Upside: +144.58%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $159.19
Upside: +151.27%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.97
Upside: +196.95%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $13.94
Upside: +14.78%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $60.60
Upside: +56.77%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $17.34
Upside: +21.14%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $458.76
Upside: +30.79%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $221.21
Upside: -3.26%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $26.96
Upside: +111.42%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $87.23
Upside: +69.68%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $4.36
Upside: -48.34%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $4.56
Upside: +17,992.11%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $43.84
Upside: -68.07%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $88.87
Upside: +12.52%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $18.68
Upside: -35.76%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $37.23
Upside: +20.87%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $149.64
Upside: +83.77%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.66
Upside: +653.30%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $7.28
Upside: +476.92%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $5.27
Upside: +1,038.52%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.59
Upside: +2,442.80%